Loeffler J S, Kooy H M, Wen P Y, Fine H A, Cheng C W, Mannarino E G, Tsai J S, Alexander E
Neurosurgical Service, Brigham and Women's Hospital, Boston, MA.
J Clin Oncol. 1990 Apr;8(4):576-82. doi: 10.1200/JCO.1990.8.4.576.
Between May 1986 and August 1989, we treated 18 patients with 21 recurrent or persistent brain metastases with stereotactic radiosurgery using a modified linear accelerator. To be eligible for radiosurgery, patients had to have a performance status of greater than or equal to 70% and have no evidence of (or stable) systemic disease. All but one patient had received prior radiotherapy, and were treated with stereotactic radiosurgery at the time of recurrence. Polar lesions were treated only if the patient had undergone and failed previous complete surgical resection (10 patients). Single doses of radiation (900 to 2,500 cGy) were delivered to limited volumes (less than 27 cm3) using a modified 6MV linear accelerator. The most common histology of the metastatic lesion was carcinoma of the lung (seven patients), followed by carcinoma of the breast (four patients), and melanoma (four patients). With median follow-up of 9 months (range, 1 to 39), all tumors have been controlled in the radiosurgery field. Two patients failed in the immediate margin of the treated volume and were subsequently treated with surgery and implantation of 125I to control the disease. Radiographic response was dramatic and rapid in the patients with adenocarcinoma, while slight reduction and stabilization occurred in those patients with melanoma, renal cell carcinoma, and sarcoma. The majority of patients improved neurologically following treatment, and were able to be withdrawn from corticosteroid therapy. Complications were limited and transient in nature and no cases of symptomatic radiation necrosis occurred in any patient despite previous exposure to radiotherapy. Stereotactic radiosurgery is an effective and relatively safe treatment for recurrent solitary metastases and is an appealing technique for the initial management of deep-seated lesions as a boost to whole brain radiotherapy.
1986年5月至1989年8月期间,我们使用改良直线加速器对18例患者的21个复发性或持续性脑转移瘤进行了立体定向放射外科治疗。符合放射外科治疗条件的患者,其体能状态须大于或等于70%,且无(或病情稳定的)全身性疾病证据。除1例患者外,所有患者均接受过先前的放疗,并在复发时接受了立体定向放射外科治疗。仅当患者先前接受过完整手术切除但失败时,才对极性病变进行治疗(10例患者)。使用改良的6MV直线加速器,将单剂量辐射(900至2500 cGy)给予有限体积(小于27 cm³)。转移瘤最常见的组织学类型是肺癌(7例患者),其次是乳腺癌(4例患者)和黑色素瘤(4例患者)。中位随访时间为9个月(范围1至39个月),放射外科治疗区域内的所有肿瘤均得到控制。2例患者在治疗体积的紧邻边缘处病情进展,随后接受了手术及125I植入以控制病情。腺癌患者的影像学反应显著且迅速,而黑色素瘤、肾细胞癌和肉瘤患者则出现轻微缩小和病情稳定。大多数患者治疗后神经功能改善,且能够停用皮质类固醇治疗。并发症有限且为一过性,尽管所有患者先前均接受过放疗,但均未发生有症状的放射性坏死病例。立体定向放射外科治疗是复发性孤立性转移瘤的一种有效且相对安全的治疗方法,作为全脑放疗的补充,对于深部病变的初始治疗是一种有吸引力的技术。